Loading...
XNAS
IMNM
Market cap1.81bUSD
Dec 05, Last price  
19.76USD
1D
-1.64%
1Q
87.83%
IPO
63.31%
Name

Immunome Inc

Chart & Performance

D1W1MN
XNAS:IMNM chart
P/E
—
P/S
200.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
59.14%
Rev. gr., 5y
%
Revenues
9m
-35.50%
0000014,018,0009,041,000
Net income
-293m
L+174.29%
-7,845,000-10,550,000-17,120,000-24,469,000-37,513,000-106,806,000-292,963,000
CFO
-111m
L+1,363.98%
-7,406,000-9,600,000-12,134,000-18,226,000-28,690,000-7,568,000-110,794,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
URL
http://immunome.com/
IPO date
Oct 02, 2020
Employees
37
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT